How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value
With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.
You may also be interested in...
Ovarian Cancer Market Snapshot: AstraZeneca's Lynparza Poised To Lead In Niche Space
AstraZeneca's Lynparza, Tesaro's Zejula and Clovis' Rubraca have brought much needed advances to patients with ovarian cancer, but the market is relatively small and the competition intense, while unmet need remains high.
AZ's Lynparza PARP Lead Likely To Lengthen With FDA Priority Review
Despite suffering a setback at the hands of NICE, AstraZeneca's ambitious plans for Lynparza have been boosted by the FDA agreeing to speed up a review of the recent SOLO-1 data which took ESMO by storm last month.
Avastin Biosimilar Battle: Amgen, Genentech File Dueling Suits
Amgen seeks declaratory judgement that its biosimilar Mvasi does not infringe 27 Genentech patents, has Genentech suit put under seal; Amgen gave 180-day commercial marketing notice on Oct. 6.